Early Clinical Experience With Networked System for Promoting Patient Self-Management
A networked system designed to promote patient self-management appears to be safe and effective in capturing, integrating, and presenting medication adherence and physiologic information.
Impact of Celecoxib Restrictions in Medicare Beneficiaries With Arthritis
A formulary restriction policy in a Medicare population was associated with lower celecoxib utilization; however, higher gastrointestinal- and arthritis-related medical costs were observed.
Using Medicare Data for Comparative Effectiveness Research: Opportunities and Challenges
July 14th 2011This review article explores the Medicare data available for researchers and approaches that could be used to enhance the data%u2019s value for comparative effectiveness research.
Adherence to Medication Under Mandatory and Voluntary Mail Benefit Designs
Pharmacy benefit designs that mandate mail pharmacy use interfere with prescription drug access, particularly for individuals without previous mail pharmacy experience.
Addressing Healthcare Inequities in Israel by Eliminating Prescription Drug Copayments
July 14th 2011In this prospective cohort study, eliminating prescription drug copayments improved blood pressure and LDL cholesterol concentration for low-income patients; glycemic control did not improve.
Colorectal Cancer Screening Use Among Insured Primary Care Patients
Colorectal cancer screening use was similar in 2 divergent primary care populations. Colonoscopy was the most frequently used modality; FOBT was used inconsistently.
Systolic Blood Pressure Control After Participation in a Hypertension Intervention Study
Systolic blood pressure control was not maintained in a large proportion of patients after the end of participation in a hypertension intervention study.
Educational outreach did not seem to be a promising strategy to promote preventive services use among patients who refused services recommended by their physician.
Cost-Effectiveness of 21-Gene Assay in Node-Positive, Early-Stage Breast Cancer
A decision-analytic model was used to estimate cost-effectiveness of adopting a 21-gene assay in treatment decisions for women with early-stage N (1-3)/ER HER2-negative breast cancer.